Understanding Progressive external ophthalmoplegia
CPEO commonly involves slowly progressive bilateral ptosis and reduced eye movements. Because limitation can be relatively symmetric and develop gradually, severe movement restriction does not necessarily produce prominent double vision. [1] [2]
Some people have mainly ocular findings; others have limb, swallowing, hearing, neurological, endocrine or cardiac involvement. “PEO-plus” describes associated features, while named syndromes and the molecular diagnosis can clarify risks. Not every person has Kearns–Sayre syndrome. [1] [3] [4]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Lids can reduce visual access
A drooping lid may obstruct the line of sight or lead to a chin-up posture. Acuity with the lid lifted and comfortable daily seeing are different outcomes. [1] [2]
Head movement replaces eye movement
Scanning, looking up or following a target may require head movement. This is not the same as a fixed loss of the retina’s peripheral field. [1] [2]
Double vision may be variable or absent
Misalignment can cause diplopia, but gradual symmetric restriction and adaptation can limit awareness. A person’s own report matters more than imposing a universal doubled scene. [1] [2]
An ocular pattern can have several molecular and functional components
Original conceptual diagram, not a diagnosis, genetic result or prediction that every organ will be affected. [1] [2] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Mitochondrial dysfunction
Different genetic mechanisms can affect energy-dependent tissues.
- Eye and lid weakness
Progressive restriction and ptosis can alter visual access.
- Separate care goals
Vision, surface protection and systemic risks need individualized assessment.
What is happening—and what remains uncertain
Mitochondria provide energy needed by muscle and other tissues. Mitochondrial DNA deletions or variants in mitochondrial or nuclear genes can impair function and cause an overlapping PEO phenotype. The same visible eye pattern can therefore arise through different molecular mechanisms. [1] [3] [4]
Genetic changes and their distribution across tissues influence test detection and clinical features. A negative blood test may not exclude some tissue-restricted mitochondrial abnormalities; the specialist chooses the testing strategy rather than assuming one sample answers every case. [3] [4]
What can look similar?
Ocular myasthenia is an important mimic
Fluctuating fatigable weakness has a different mechanism and treatment. Variability, examination and targeted testing help distinguish it from slowly progressive mitochondrial ophthalmoplegia. [1]
CFEOM starts with congenital dysinnervation
Stable congenital restriction differs from progressive mitochondrial muscle disease. Old photographs and onset history can help clarify the course. [1]
Kearns–Sayre has additional defining features
Early-onset PEO with retinal and systemic findings can fit KSS or its spectrum. The broader diagnosis affects surveillance, especially cardiac care. [3]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Assess vision, lids and movementThe eye examination separates obstruction, surface exposure, refraction, alignment, retina and optic nerve findings. Restricted gaze alone does not explain every visual complaint. [1] [2]
- Establish a molecular explanation where possibleGenetic testing and, in selected cases, tissue investigation clarify mitochondrial disease and inheritance. Older biopsy-first algorithms should not be treated as a universal current pathway. [3] [4]
- Look beyond the eyesNeuromuscular and appropriate systemic assessment considers cardiac conduction, hearing, swallowing and other manifestations. The plan depends on phenotype and molecular findings, not a syndrome-wide assumption that every complication will occur. [2] [3]
What may help—and what is still being studied
Treat specific visual barriers
Selected glasses, prism or supervised occlusion may help a task when misalignment is symptomatic. They do not change the mitochondrial cause or restore all ocular movement. [1] [2]
What this can mean for daily life
Arrange a comfortable viewing zone
Place important information where useful gaze and head posture are possible. Discuss neck strain and access rather than forcing a standard posture. [1]
Use accessible text and audio
Magnification, text-to-speech and task adjustments can reduce the burden of obstructed or unstable viewing when individually helpful. Low-vision assessment can separate useful aids from unnecessary restrictions. [2]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
Clinical, pathological and genetic spectrum in 89 cases of mitochondrial PEO
Identified ocular-only, KSS and PEO-plus patterns with several molecular causes. [4]
Limits and applicability: Selected specialist cohort; high diagnostic yield and biopsy-first proposal do not dictate testing for every current patient or predict genotype from appearance.
Patient care standards for primary mitochondrial disease
Includes ocular assessment, corneal safety, low-vision support and systemic care. [2]
Limits and applicability: Broad primary-mitochondrial consensus rather than CPEO-specific comparative trials; later molecular and regional guidance may refine practice.
Mitochondrial Chronic Progressive External Ophthalmoplegia
Summarizes clinical/genetic heterogeneity and individualized supportive treatment. [1]
Limits and applicability: Review-level synthesis; case-series surgical outcomes and mechanistic therapies are not proof of a durable disease-modifying treatment.
Questions researchers still need to answer
- Which molecular and tissue-testing pathways provide the best diagnostic yield with the least burden?
- Which interventions improve long-term visual function while preserving corneal safety?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
United Mitochondrial Disease Foundation
Mitochondrial-disease education, support and a calendar including virtual meetings. These cover multiple mitochondrial diagnoses; a listed treatment or trial is not automatically relevant to this condition.
Connections listed by the organization.
The Lily Foundation
Broader mitochondrial-disease family support, education and research information. Regional eligibility and available practical help should be checked with the organization; not a condition-specific treatment service.
Mito Foundation: CPEO
Condition-focused information and Australian care pathways. Local access and eligibility differ from other countries.
MedlinePlus Genetics: progressive external ophthalmoplegia
Accessible introduction to phenotype and genetic diversity, for discussion with the care team.
Questions you may still have
Why is double vision sometimes absent?
Restriction may progress gradually and fairly symmetrically, allowing adaptation. This does not mean movements or visual access are normal. [1] [2]
Does CPEO always mean Kearns–Sayre?
No. PEO is a broader pattern with multiple causes and associated-feature combinations. KSS has additional clinical criteria. [3] [4]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- Mitochondrial Chronic Progressive External Ophthalmoplegia (2024; review).
Original indexed review/PDF text checked; publisher direct access rate-limited.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Parikh et al.: Patient care standards for primary mitochondrial disease (2017; guideline).
Indexed original consensus sections checked; published2017 despite later PMC deposit.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Goldstein and Falk: Single Large-Scale Mitochondrial DNA Deletion Syndromes, GeneReviews (2023; review).
Deletion-specific scope; not every molecular cause of PEO.
Checked 2026-10-24 · Public page checked - Rodríguez-López et al.: Clinical, pathological and genetic spectrum in 89 cases of mitochondrial PEO (2020; observational).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - MedlinePlus Genetics: Progressive external ophthalmoplegia (n.d.; institution).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Shortness of breath: emergency warning signs (n.d.; institution).
Severe breathing difficulty, gasping, choking or inability to speak require emergency help; other breathing difficulty has a separate urgent route. UK numbers are not generalized.
Checked 2026-10-24 · Public page checked - NHS — Symptoms of a stroke (2024; institution).
Sudden weakness, speech difficulty and sight changes can be stroke signs requiring emergency action, including signs within the last24 hours that have resolved; UK emergency number is not generalized.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.